Cargando…

Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis

OBJECTIVE: We aimed to further investigate the efficacy and safety of low-dose NOACs by performing a meta-analysis of cohort studies. BACKGROUND: Meta-analyses of randomized controlled trials (RCTs) have demonstrated that low-dose non-vitamin K antagonist oral anticoagulants (NOACs) showed inferior...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ze, Wang, Xiaozhen, Li, Dandan, Wen, Aiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017587/ https://www.ncbi.nlm.nih.gov/pubmed/35449605 http://dx.doi.org/10.1155/2022/4713826

Ejemplares similares

Low-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis
por: Li, Ze, et al.
Publicado: (2022)

Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement
por: Wu, Victor Chien-Chia, et al.
Publicado: (2020)

Reply to Letter to the Editor: “How to Optimize Administration of Low-Dose NOACs in Everyday Practice?”
por: Li, Ze, et al.
Publicado: (2022)

NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis
por: Hicks, Tim, et al.
Publicado: (2016)

Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis
por: Melgaard, Line, et al.
Publicado: (2021)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Lack of reversibility for NOACs
por: Al-Kindi, Sadeer
Publicado: (2014)

TAVR: nemesis of NOACs?
por: Polzin, Amin, et al.
Publicado: (2022)

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain
por: Escobar Cervantes, Carlos, et al.
Publicado: (2022)

Response to ‘Lack of reversibility for NOACs’
por: Kaba, Riyaz A, et al.
Publicado: (2014)

Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a dedicated NOAC clinic
por: de Veer, A. J. W. M., et al.
Publicado: (2019)

Reversal agents for NOACs: Connecting the dots
por: Dalal, Jamshed, et al.
Publicado: (2016)

DVT prophylaxis in critical care: role of NOACS
por: Lancé, Marcus D.
Publicado: (2019)

Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs
por: Altman, Raul, et al.
Publicado: (2014)

NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement
por: Piepiorka-Broniecka, Marta, et al.
Publicado: (2022)

Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
por: He, Qiyu, et al.
Publicado: (2019)

Do Patients with Atrial Fibrillation and a History of Ischemic Stroke Overuse Reduced Doses of NOACs?—Results of the Polish Atrial Fibrillation (POL-AF) Registry
por: Szyszkowska, Anna, et al.
Publicado: (2022)

Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis
por: Liu, Fuwei, et al.
Publicado: (2022)

Erratum to: NOACs for secondary stroke prevention in patients with atrial fibrillation
Publicado: (2020)

Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding
por: Lee, Min-Taek, et al.
Publicado: (2020)

Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms
por: Saviano, Angela, et al.
Publicado: (2022)

Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry
por: Liu, Chang, et al.
Publicado: (2019)

A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
por: Kim, Hyeongsoo, et al.
Publicado: (2020)

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
por: Blann, Andrew
Publicado: (2015)

Is Initiating NOACs for Atrial Arrhythmias Safe in Adults with Congenital Heart Disease?
por: Yang, Hayang, et al.
Publicado: (2017)

Abstract 28. Novel Oral Anticoagulants (NOACs) in Microsurgery: A Review
por: Yao, Amy, et al.
Publicado: (2017)

New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
por: Rutherford, Ole-Christian Walter, et al.
Publicado: (2018)

New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study
por: Altay, Servet, et al.
Publicado: (2017)

NOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy Actions
por: Di Cesare, Mariachiara, et al.
Publicado: (2020)

Periinterventional Management of Edoxaban in Major Procedures: Results from the DRESDEN NOAC REGISTRY
por: Köhler, Christina, et al.
Publicado: (2023)

Pleiotropic effects of NOACs with focus on edoxaban: scientific findings and potential clinical implications
por: Goette, Andreas, et al.
Publicado: (2023)

Anticoagulant Treatment in Patients with AF and Very High Thromboembolic Risk in the Era before and after the Introduction of NOAC: Observation at a Polish Reference Centre
por: Bielecka, Bernadetta, et al.
Publicado: (2023)

Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?
por: Lin, Yi-Pin, et al.
Publicado: (2015)

Correction: New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
Publicado: (2020)

Consideration of NOACs (novel or non-vitamin K-dependent oral anticoagulants) in dental procedure
por: Song, Jiyoung
Publicado: (2021)

Post-TAVR patients with atrial fibrillation: are NOACs better than VKAs?—A meta-analysis
por: Wang, Lu, et al.
Publicado: (2023)

Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry
por: Renda, Giulia, et al.
Publicado: (2020)

Implementation and Evaluation of a Standardized Non–Vitamin K Oral Anticoagulant (NOAC) Patient Safety Alert Card Across the Northern Region of England
por: Thomas, Honey, et al.
Publicado: (2020)

Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing
por: Diel, Roland, et al.
Publicado: (2019)

Access Site Bleeding Complications with NOACs versus VKAs in Patients with Atrial Fibrillation Undergoing Cardiac Implantable Device Intervention
por: Spinoni, Enrico Guido, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hvqi599qk3ouu8qgf4hduib57a